Wild-Type (jvs+/+) | Heterozygous (jvs+/-) | |||||
---|---|---|---|---|---|---|
Vehicle | VPA | Vehicle | VPA | |||
Free carnitine | 31.3 ± 2.7 | 13.1 ± 1.7* | 22.4 ± 2.0* | 7.9 ± 1.7†‡ | ||
SCA carnitine | 10.1 ± 3.4 | 14.6 ± 2.1* | 11.0 ± 1.5 | 11.1 ± 1.4 | ||
TAS carnitine | 41.4 ± 1.2 | 27.6 ± 1.4* | 33.6 ± 1.2* | 19.0 ± 0.9†‡ | ||
LCA carnitine | 6.6 ± 1.3 | 9.0 ± 0.9* | 4.2 ± 1.2* | 4.1 ± 0.5† | ||
SCA/TAS carnitine | 0.24 ± 0.08 | 0.53 ± 0.06* | 0.33 ± 0.04 | 0.58 ± 0.08‡ | ||
Total carnitine | 48.0 ± 1.2 | 36.6 ± 2.3* | 37.8 ± 2.2* | 23.1 ± 1.2†‡ |
LCA, long-chain-acylcarnitine; SCA, short-chain-acylcarnitine; TAS, total acid-soluble carnitine.
↵* P < 0.05, vehicle-treated mice jvs+/- mice or VPA-treated wild-type mice vs. vehicle-treated wild-type mice.
↵† P < 0.05, VPA-treated jvs+/- mice vs. VPA-treated wild-type mice.
↵‡ P < 0.05, VPA-treated jvs+/- vs. vehicle-treated jvs+/- mice.